Trevi Therapeutics (TRVI) to Release Quarterly Earnings on Tuesday

Key Points

• Trevi Therapeutics will report its Q4 2025 results before the market opens on Tuesday, March 17, with analysts forecasting earnings of ($0.10) per share; the company’s earnings call is scheduled for Wednesday, March 18 at 4:00 PM ET.
• Shares opened at $11.70 on Tuesday after sliding about 12%, giving Trevi a market cap near $1.50 billion and a 52‑week range of $4.85–$14.39.
• Analysts are broadly positive: the consensus rating is "Buy" (two Strong Buy, eight Buy, one Sell) with an average price target of $21.10, implying substantial upside from the current price.

Trevi Therapeutics (NASDAQ:TRVI - Get Free Report) is expected to be announcing its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect Trevi Therapeutics to post earnings of ($0.10) per share for the quarter. Interested persons may review the information on the company's upcoming Q4 2025 earning report for the latest details on the call scheduled for Wednesday, March 18, 2026 at 4:00 PM ET.

Trevi Therapeutics Stock Down 12.0%

Shares of TRVI opened at $11.70 on Tuesday. The company has a market capitalization of $1.50 billion, a price-to-earnings ratio of -31.62 and a beta of 0.94. Trevi Therapeutics has a 52 week low of $4.85 and a 52 week high of $14.39. The stock's 50-day moving average price is $11.24 and its 200-day moving average price is $10.76.

Institutional Trading of Trevi Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Russell Investments Group Ltd. lifted its position in shares of Trevi Therapeutics by 194.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 4,536 shares of the company's stock valued at $25,000 after buying an additional 2,996 shares in the last quarter. Strs Ohio purchased a new stake in Trevi Therapeutics in the 1st quarter worth $52,000. Abel Hall LLC purchased a new stake in Trevi Therapeutics in the 4th quarter worth $128,000. Rafferty Asset Management LLC acquired a new position in Trevi Therapeutics during the second quarter worth $60,000. Finally, Creative Planning raised its position in Trevi Therapeutics by 17.5% during the second quarter. Creative Planning now owns 20,247 shares of the company's stock worth $111,000 after acquiring an additional 3,016 shares during the period. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on TRVI shares. Morgan Stanley boosted their price target on Trevi Therapeutics from $18.00 to $19.00 and gave the company an "overweight" rating in a report on Friday, November 14th. Oppenheimer reaffirmed an "outperform" rating on shares of Trevi Therapeutics in a research note on Monday. Leerink Partners boosted their target price on shares of Trevi Therapeutics from $13.00 to $16.00 and gave the company an "outperform" rating in a research note on Wednesday, November 19th. D. Boral Capital reissued a "buy" rating and set a $19.00 price target on shares of Trevi Therapeutics in a report on Monday. Finally, HC Wainwright restated a "buy" rating and set a $21.00 price target on shares of Trevi Therapeutics in a research report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $21.10.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel non-opioid therapies for the management of chronic and acute pain. The company leverages proprietary drug delivery platforms and targeted molecular approaches to address high unmet needs in cancer-related pain, chemotherapy-induced neuropathy and other severe pain conditions.

Its lead product candidate is a proprietary formulation of tetrodotoxin (TTX), a sodium-channel blocking agent being evaluated in early-stage clinical trials for moderate-to-severe pain associated with advanced cancer and peripheral neuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.